You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Ascelia Pharma: Potential milestones in 2024
Wrap up on potentiel milestones in 2024 with CEO Magnus Corfitzen and Deputy CEO Julie Brogren.
Orviglance - readout results in May 2024, Oncoral upstart of Phase 2 trials, Go-to-market strategy is well prepared and focused and finally funding secured until Q2-2025
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement.